CHRONIC LYMPHOCYTIC LEUKEMIA CLL MUTATIONS DETECTION PANEL 2 Test
At DNA Labs UAE, we offer the CHRONIC LYMPHOCYTIC LEUKEMIA CLL MUTATIONS DETECTION PANEL 2 test. This diagnostic test is designed to identify specific genetic mutations associated with CLL.
Test Components
- SF3B1 K700E mutation
- MYD88 L265P mutation
- NOTCH1 p.2514*fs mutation
- PTEN loss at 10q23.31
- 11q deletion
- Trisomy 12
- 13q14 deletion
- 14q deletion
- 17p deletion
- Trisomy 19
Test Cost: AED 820.0
Sample Condition
For this test, we require 4 mL (2 mL min.) of whole blood from 1 Lavender top (EDTA) tube. The sample should be shipped refrigerated and must not be frozen. Additionally, a duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Report Delivery
The sample should be submitted by Monday at 11 am, and the report will be delivered on Saturday.
Method
This test is performed using PCR – MLPA (Polymerase Chain Reaction – Multiplex Ligation-dependent Probe Amplification) method.
Test Type
This test falls under the category of Cancer tests.
Doctor
This test is typically referred by an Oncologist.
Test Department
This test is conducted in the Molecular Diagnostics department.
Pre Test Information
A duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory before undergoing this test.
Test Details
The Chronic Lymphocytic Leukemia (CLL) Mutations Detection Panel 2 test is a diagnostic test used to identify specific genetic mutations associated with CLL. This test helps in determining the prognosis and treatment options for individuals with CLL. CLL is a type of cancer that affects the white blood cells, specifically the lymphocytes. Mutations in certain genes can contribute to the development and progression of CLL.
The CLL Mutations Detection Panel 2 test analyzes specific genes, such as TP53, NOTCH1, SF3B1, and others, to identify mutations that may be present in CLL patients. By identifying these mutations, healthcare providers can better understand the individual’s disease progression and select appropriate treatment options. For example, certain mutations may indicate a more aggressive form of CLL that may require more intensive therapy.
The CLL Mutations Detection Panel 2 test is typically performed on a blood sample. The sample is sent to a laboratory where specialized techniques, such as DNA sequencing or polymerase chain reaction (PCR), are used to analyze the genetic material and identify any mutations.
It is important to note that this test is specific to CLL and may not be applicable to other types of leukemia or lymphoma. Additionally, the test may not detect all possible mutations associated with CLL, as new mutations are constantly being discovered.
Overall, the CLL Mutations Detection Panel 2 test is a valuable tool in the diagnosis and management of CLL, providing important information about an individual’s disease and guiding treatment decisions.
| Test Name | CHRONIC LYMPHOCYTIC LEUKEMIA CLL MUTATIONS DETECTION PANEL 2 Test |
|---|---|
| Components | *SF3B1 K700E mutation*MYD88 L265P mutation*NOTCH1 p.2514*fs mutation *PTEN loss at 10q23.31*11q deletion *Trisomy 12*13q14 deletion*14q deletion*17p deletion*Trisomy 19 |
| Price | 820.0 AED |
| Sample Condition | 4 mL (2 mL min.) whole blood from 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
| Report Delivery | Sample Mon by 11 am;ReportSat |
| Method | PCR – MLPA |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
| Test Details |
The Chronic Lymphocytic Leukemia (CLL) Mutations Detection Panel 2 test is a diagnostic test used to identify specific genetic mutations associated with CLL. This test helps in determining the prognosis and treatment options for individuals with CLL. CLL is a type of cancer that affects the white blood cells, specifically the lymphocytes. Mutations in certain genes can contribute to the development and progression of CLL. The CLL Mutations Detection Panel 2 test analyzes specific genes, such as TP53, NOTCH1, SF3B1, and others, to identify mutations that may be present in CLL patients. By identifying these mutations, healthcare providers can better understand the individual’s disease progression and select appropriate treatment options. For example, certain mutations may indicate a more aggressive form of CLL that may require more intensive therapy. The CLL Mutations Detection Panel 2 test is typically performed on a blood sample. The sample is sent to a laboratory where specialized techniques, such as DNA sequencing or polymerase chain reaction (PCR), are used to analyze the genetic material and identify any mutations. It is important to note that this test is specific to CLL and may not be applicable to other types of leukemia or lymphoma. Additionally, the test may not detect all possible mutations associated with CLL, as new mutations are constantly being discovered. Overall, the CLL Mutations Detection Panel 2 test is a valuable tool in the diagnosis and management of CLL, providing important information about an individual’s disease and guiding treatment decisions. |
